ABSTRACT
We conducted a test negative study from November 2023 to June 2024, enrolling 4,367 children hospitalized with acute respiratory illness in Hong Kong. Among the children who tested negative for influenza virus and SARS-CoV-2, 56.8% had received influenza vaccination. Between November 2023 and March 2024, influenza A(H3N2) predominated and the VE against influenza A(H3N2) was estimated as 55% (95% CI: 29.6%, 71.8%). VE point estimates were higher for younger children than older children. In February to June 2024 influenza A(H1N1) predominated and VE against influenza A(H1N1) was 54% (95% CI: 33%, 69%) during this period. Influenza B circulated at low intensity throughout the 2023/24 season and VE against influenza B was 66% (95% CI: 42%, 80%). Since its introduction in 2018/19 the school-based influenza vaccination program has substantially increased vaccine uptake in children in Hong Kong and prevented influenza-associated hospitalizations.
Competing Interest Statement
BJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. SGS has consulted for Moderna, Novavax, Pfizer, Evo Health, and CSL Seqirus. The authors report no other potential conflicts of interest.
Funding Statement
This research was financially supported by a grant from the Health and Medical Research Fund, Health Bureau, the Government of the Hong Kong Special Administrative Region (grant number INF-HKU-3). BJC is supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. 75N93021C00015, the Theme-based Research Scheme (grant number T11-712/19-N) of the Research Grants Council of the Hong Kong SAR Government, and an RGC Senior Research Fellowship from the University Grants Committee (grant number HKU SRFS2021-7S03).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study protocol was approved by the Institutional Review Board of the Hospital Authority Hong Kong West Cluster and the Hospital Authority Kowloon West Cluster Research Ethics Committee. Verbal consent was obtained from the parents or legal guardians of participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
